Axumin® (fluciclovine F 18) injection patient case studies
These case studies are being provided to you as examples of the images and information available following Axumin PET/CT imaging in patients with biochemically recurrent prostate cancer. The responsibility for the accurate and timely acquisition and interpretation of images using Axumin PET/CT scanning rests with the nuclear medicine physician or radiologist supervising the PET/CT imaging facility. These case studies are not intended to substitute for the independent medical judgment of the physician(s) responsible for the individual patient’s management, nor are they a guarantee of any specific clinical results. Incidental findings are noted in some of the cases, as examples of potential, unanticipated abnormalities that may be identified during interpretation of Axumin images. The diagnostic efficacy of Axumin for the identification of these incidental abnormalities has not been established and confirmatory testing may be considered appropriate. The following case studies are provided as examples of the interpretation and utility of Axumin® PET/CT imaging results. Axumin is not indicated for directing or changing patient management. Such decisions must be based on the independent medical judgment of the physician(s) responsible for the individual patient’s management. These case studies are post marketing, on label, and, at present, there is nothing to suggest that adverse events potentially change Axumin’s safety profile.
*Please note that reviewing these case studies is not a substitute for Axumin Image Interpretation Training. For information on Axumin Image Interpretation Training, please follow the instructions here.